Is Canopy Growth (TSX:WEED) Stock a Buy Right Now?

Canopy Growth (TSX:WEED) remains a top pick for long-term marijuana investors.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canadian cannabis companies continue to underperform the broader markets in 2020. The extended bear run in pot stocks started in early 2019 and has burnt massive investor wealth. For example, marijuana heavyweight Canopy Growth (TSX:WEED)(NYSE:CGC) is trading at $32, which is 55% below its record high.

However, since the start of October, Canopy Growth stock has gained 71% on the back of its quarterly results and a Joe Biden win. Let’s take a look to see if you should buy this cannabis stock right now.

Canopy Growth reported record Q2 sales

Last week, Canopy Growth disclosed its fiscal second-quarter of 2021 results and reported revenue of $135.3 million — year-over-year growth of 77% and sequential growth of 23%. Revenue was also higher compared to the analyst forecast of $117.2 million.

While Canopy’s strong domestic sales were the highlight in the September quarter, its international sales were down 3% to $17.5 million. The company attributed this decline to a packaging supply issue as well as sluggish growth coupled with an increase in competition in Germany’s dried flower market.

Canopy Growth is one of the largest brands in Canada’s recreational marijuana space. It ended Q2 with a market share of 15.5%, an increase of 200 basis points year over year. The company’s market share grew by 190 basis points in Ontario which is Canada’s most heavily populated province while it lost market share in Alberta.

Canopy is also dominating the Cannabis 2.0 beverage space in Canada with a 54% dollar share. It has launched five THC cannabis beverages and recently entered the CBD beverage vertical as well.

Earlier this month, in an interview with CNBC’s Mad Money, Canopy CEO David Klein said cannabis-infused edibles and drinks would be key revenue drivers for the firm in the upcoming decade.

Canopy’s narrowing loss a key metric

Despite record revenue in Q2, Canopy Growth continues to post a net loss. In Q2, its net loss stood at $96.6 million, significantly lower compared to its net loss of $128 million in the previous quarter. Its adjusted EBITDA loss was $85.7 million compared with an EBITDA loss of $150 million in the prior-year period and a loss of $92 million in the June quarter.

Canopy is accelerating its path towards profitability, and this bottom-line improvement was cheered by investors. Analysts expect Canopy’s net loss per share to improve from $1.61 in fiscal 2020 to $0.78 in 2022. This means it will take the company at least three years to report an adjusted net income.

Klein has trained his guns on improving Canopy’s bottom line, and the company has deployed several cost-cutting measures this year. The management has identified between $150 million and $200 million in cost-savings opportunities across its manufacturing and operating verticals.

The Foolish takeaway

Canopy Growth is one of the largest cannabis companies in the world. Its leadership position makes the stock a relatively safe bet in a sector that is grappling with a number of structural issues. It is also backed by Constellation Brands and does not have to worry about its high cash burn at the moment.

The legalization of marijuana south of the border will be one of the major drivers for Canopy and its peers. However, this is something that is not in the company’s control.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of and recommends Constellation Brands. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »